WINNERSH, UNITED KINGDOM--(Marketwired - Jul 11, 2013) - Vernalis PLC (LSE: VER)

11 July 2013


         Notice of Results for the Six Months Ended 30 June 2013

Vernalis plc today announces its half year results for the six months
ended 30 June 2013 will be released on Monday, 29 July 2013. The
earnings announcement will be distributed at 7:00 am (UK) and will be
available to download from .

Following the results announcement, the Company will host an analyst
presentation and concurrent conference call at 9:30 am (UK) on 29 July
2013. The presentation will be held at the offices of Brunswick Group,
16 Lincoln's Inn Fields, London, WC2A 3ED. Please contact Valerie
Mugridge at Brunswick on +44 (0) 207 396 5325 for details.

                             -- ends --


Vernalis Contacts:
Ian Garland, Chief Executive Officer       +44 (0) 118 938 0015
David Mackney, Chief Financial Officer

Nomura Code Securities Limited:            +44 (0) 20 7776 1200
Juliet Thompson
Jonathan Senior

Brunswick Group:                           +44 (0) 20 7404 5959
Jon Coles

Notes to Editors

About Vernalis

Vernalis is a revenue generating development stage pharmaceutical
company with significant expertise in drug development. The Group has
one marketed product, frovatriptan for the acute treatment of migraine,
an exclusive licensing agreement to develop and commercialise multiple
novel products focussed on the US prescription cough cold market as
well as seven programmes in its NCE development pipeline. Vernalis has
also significant expertise in fragment and structure based drug
discovery which it leverages to enter into collaborations with larger
pharmaceutical companies. The Company's technologies, capabilities and
products have been endorsed over the last five years by collaborations
with leading pharmaceutical companies, including Biogen Idec, Endo,
GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

For further information about Vernalis, please visit 

Vernalis Forward-Looking Statement

This news release may contain forward-looking statements that reflect
the Company's current expectations regarding future events including
the clinical development and regulatory clearance of the Company's
products, the Company's ability to find partners for the development
and commercialisation of its products, as well as the Company's future
capital raising activities. Forward-looking statements involve risks
and uncertainties. Actual events could differ materially from those
projected herein and depend on a number of factors including the
success of the Company's research strategies, the applicability of the
discoveries made therein, the successful and timely completion ofclinical
studies, the uncertainties related to the regulatory process,
the ability of the Company to identify and agree beneficial terms with
suitable partners for the commercialisation and/or development of its
products, as well as the achievement of expected synergies from such
transactions, the acceptance of frovatriptan and other products by
consumers and medical professionals, the successful integration of
completed mergers and acquisitions and achievement of expected
synergies from such transactions, and the ability of the Company to
identify and consummate suitable strategic and business combination

                    This information is provided by RNS
          The company news service from the London Stock Exchange


Contact Information: